



From ANA to ENA: daily practice in the Netherlands

Jan Damoiseaux





Harmonisation of Testing Algorithms

Questionnaire

Categories:

- Organisation (n=4),
- ANA testing (n=14),
- Anti-dsDNA ab testing (n=8),
- Anti-ENA ab testing (n=15),
- ANA/ENA algorithm (n=16).





. .

Response

Send out to 81 laboratories:

- Dutch diagnostic laboratories (n=76),
- Foreign diagnostic laboratories (n=2),
- Diagnostic compagnies (n=3),

 \rightarrow 66 questionnaires were returned from the Dutch diagnostic laboratories (87%)



ANA testing





ANA testing



ANA methods

European Autoimmunity Standardisation Initiative





ANA methods

European Autoimmunity Standardisation Initiative



the FEIA ENA screen



ANA testing

European Autoimmunity Standardisation Initiative





ANA titration





ANA Titration

Yes (3)

□ No (14)





European Autoimmunity Standardisation Initiative

anti-dsDNA ab Testing





European Autoimmunity Standardisation Initiative



Method for detection

95%



European Autoimmunity Standardisation Initiative





Anti-ENA ab testing

European Autoimmunity Standardisation Initiative

anti-ENA ab testing





€ΛSi™ **European Autoimmunity** Standardisation Initiative



Method for detection



€ΛSi™ European Autoimmunity Standardisation Initiative



Method for detection

















- 1. ANA testing should be part of autoantibody detection in systemic autoimmune diseases.
- 2. ANA tests based on a (restricted) mixture of defined antigens should not be referred to as ANA test.
- 3. Positive ANA IIF results should be reported in a semiquantitative way (fluorescence intensity or titration).
- 4. Reading the ANA IIF pattern is recommended; report to clinician is optional.
- 5. The method used for anti-dsDNA antibodies should be communicated to the clinician.





- 6. Results of anti-dsDNA antibody tests should be reported quantitatively.
- The 7 "standard" ENA (SSA, SSB, Sm, RNP, CENP-B, Scl-70, and Jo-1) should all be typed.
- 8. Results of the 7 "standard" ENA should all be reported separately, preferentially in a qualitative way.
- 9. Anti-SSA60 and anti-Ro52 antibodies should be distinguished and reported separately.
- 10. In case of suspicion of CHB/NL the presence of anti-Ro52 antibodies should be tested.





- 11. Detection of anti-Sm antibodies should be SmD specific, but may be reported as anti-Sm.
- 12. The anti-dsDNA antibody test should be available as a rapid test.
- 13. An homogenous ANA (IIF) result during the diagnostic work-up should be followed by an anti-dsDNA ab test.
- 14. A positive ANA test result during the diagnostic workup should be followed by an anti-ENA ab test.
- 15. Clinical suspicion of myositis, CHB/NL, or Sjögren's syndrome always requires anti-ENA ab detection.



Acknowledgements



Liesbeth Bakker-Jonges

Jan Willem Cohen Tervaert Ron Derksen Dörte Hamann Herbert Hooijkaas Cees Kallenberg Ina Klasen Pieter Limburg Ruud Smeenk